A high consensus was reached by the SCMs on the effectiveness of PARPi in reducing recurrence and extending survival in BRCA carriers with high-risk HR-positive/HER2-negative BC; including PARPi in the treatment plan for high-risk BRCA carriers with HR-positive/HER2-negative eBC; and preferring endocrine therapy (ET) + PARPi over ET + cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) for high-risk HR-positive/HER2-negative eBC. The gene discussed is CDK4; the disease is breast cancer.